Published in BMC Genet on December 30, 2005
Robust ranks of true associations in genome-wide case-control association studies. BMC Proc (2007) 0.80
William Allan Award Address: On the role and soul of a statistical geneticist. Am J Hum Genet (2011) 0.75
From genotypes to genes: doubling the sample size. Biometrics (1997) 11.46
Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res (2001) 9.41
A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res (2001) 6.06
Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered (2002) 4.64
Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet (2001) 4.09
Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered (2001) 2.14
Extension of the Haseman-Elston method to multiple alleles and multiple loci: theory and practice for candidate genes. Ann Hum Genet (1997) 1.21
Efficiency robust tests for survival or ordered categorical data. Biometrics (1999) 1.19
A single, sequential, genome-wide test to identify simultaneously all promising areas in a linkage scan. Genet Epidemiol (2000) 1.02
Robust trend tests for genetic association in case-control studies using family data. BMC Genet (2005) 0.99
Bivariate genome scans incorporating factor and principal component analyses to identify common genetic components of alcoholism, event-related potential, and electroencephalogram phenotypes. BMC Genet (2005) 0.85
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med (2013) 6.21
Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med (2015) 4.77
Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell (2003) 4.73
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater (2011) 3.40
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet (2011) 3.18
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med (2015) 3.11
Microarray-based analysis of stress-regulated microRNAs in Arabidopsis thaliana. RNA (2008) 3.09
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Polycystin-2 traffics to cilia independently of polycystin-1 by using an N-terminal RVxP motif. J Cell Sci (2006) 2.72
Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet (2013) 2.71
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Activatable photosensitizers for imaging and therapy. Chem Rev (2010) 2.23
Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet (2008) 2.23
Loss of oriented cell division does not initiate cyst formation. J Am Soc Nephrol (2009) 2.20
Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol (2006) 2.08
Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest (2004) 2.00
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet (2009) 1.96
Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet (2007) 1.90
Increased postoperative and respiratory complications in patients with congenital heart disease associated with heterotaxy. J Thorac Cardiovasc Surg (2010) 1.74
Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA (2012) 1.72
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest (2014) 1.71
Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest (2004) 1.67
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
Linkage disequilibrium mapping of quantitative-trait Loci by selective genotyping. Am J Hum Genet (2005) 1.64
Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail (2006) 1.61
Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics (2006) 1.57
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
Efficient approximation of P-value of the maximum of correlated tests, with applications to genome-wide association studies. Ann Hum Genet (2008) 1.46
Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension (2009) 1.45
Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol (2006) 1.44
Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet (2002) 1.44
Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 1.44
High prevalence of respiratory ciliary dysfunction in congenital heart disease patients with heterotaxy. Circulation (2012) 1.44
Testing association for markers on the X chromosome. Genet Epidemiol (2007) 1.43
Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem (2007) 1.41
Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc Natl Acad Sci U S A (2007) 1.41
Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J (2003) 1.41
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica (2009) 1.31
Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res (2011) 1.30
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest (2009) 1.28
Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. J Biol Chem (2011) 1.26
Syntaxin 5 regulates the endoplasmic reticulum channel-release properties of polycystin-2. Proc Natl Acad Sci U S A (2008) 1.26
Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano (2014) 1.23
A differential role for endocytosis in receptor-mediated activation of Nox1. Antioxid Redox Signal (2010) 1.20
Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin Trials (2010) 1.18
Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1. Am J Pathol (2008) 1.17
Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjug Chem (2003) 1.17
HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small (2010) 1.17
Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med (2010) 1.17
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
Intrinsically copper-64-labeled organic nanoparticles as radiotracers. Angew Chem Int Ed Engl (2012) 1.16
A robust genome-wide scan statistic of the Wellcome Trust Case-Control Consortium. Biometrics (2009) 1.15
Porphyrin shell microbubbles with intrinsic ultrasound and photoacoustic properties. J Am Chem Soc (2012) 1.14
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Venous blood ammonia can be associated with cerebral blood flow in hepatic encephalopathy. Hepatology (2013) 1.12
Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers. Biosens Bioelectron (2004) 1.10
Identification of two novel polycystic kidney disease-1-like genes in human and mouse genomes. Genomics (2003) 1.09
Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia (2006) 1.09
Cardiovascular assessment of fetal mice by in utero echocardiography. Ultrasound Med Biol (2008) 1.08
MAX-rank: a simple and robust genome-wide scan for case-control association studies. Hum Genet (2008) 1.08
Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. Bioconjug Chem (2007) 1.07
Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew Chem Int Ed Engl (2012) 1.06
Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol (2009) 1.05
Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J (2008) 1.05
Redox ratio of mitochondria as an indicator for the response of photodynamic therapy. J Biomed Opt (2004) 1.04
Multistage sampling for genetic studies. Annu Rev Genomics Hum Genet (2007) 1.04
Altered brain functional connectivity in patients with cirrhosis and minimal hepatic encephalopathy: a functional MR imaging study. Radiology (2012) 1.04
Improving power for testing genetic association in case-control studies by reducing the alternative space. Biometrics (2009) 1.01
Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease. Blood (2002) 1.01
Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.01
Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. Toxicol Sci (2008) 1.01
High-throughput functional microRNAs profiling by recombinant AAV-based microRNA sensor arrays. PLoS One (2012) 1.01
Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc (2007) 1.00
Efficiency robust statistics for genetic linkage and association studies under genetic model uncertainty. Stat Med (2010) 1.00
Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging. J Am Chem Soc (2011) 1.00
Robust trend tests for genetic association in case-control studies using family data. BMC Genet (2005) 0.99
Robust tests for single-marker analysis in case-control genetic association studies. Ann Hum Genet (2009) 0.99
Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol Imaging (2008) 0.98
Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging. Springerplus (2013) 0.98
Ablation of hypoxic tumors with dose-equivalent photothermal, but not photodynamic, therapy using a nanostructured porphyrin assembly. ACS Nano (2013) 0.97
Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small (2011) 0.97
Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl (2009) 0.97
Community health service capacity in China: a survey in three municipalities. J Eval Clin Pract (2011) 0.97
When to stop a clinical trial early for benefit: lessons learned and future approaches. Circ Heart Fail (2012) 0.95
Near-infrared optical imaging of B16 melanoma cells via low-density lipoprotein-mediated uptake and delivery of high emission dipole strength tris[(porphinato)zinc(II)] fluorophores. Bioconjug Chem (2005) 0.95
Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development. Toxicol Appl Pharmacol (2006) 0.95
Altered regional homogeneity in the development of minimal hepatic encephalopathy: a resting-state functional MRI study. PLoS One (2012) 0.95
Structural and functional abnormalities of default mode network in minimal hepatic encephalopathy: a study combining DTI and fMRI. PLoS One (2012) 0.95
Multimodal bacteriochlorophyll theranostic agent. Theranostics (2011) 0.95